BioSpace News Archive

Codex DNA, Inc. today announced a plan to change its Company name to Telesis Bio.

Gamma Biosciences, a leading provider of tools and technologies for cell and gene therapy manufacturing, through their BioMagnetic Solutions business, today announced a strategic collaboration with Lonza.

Alphatec Holdings, Inc. announced that at the 2022 NASS Annual Meeting, the Company will introduce expandable interbody and access technology designed to enhance the medialized minimally-invasive posterior approach.

Neurelis, Inc., a commercial-stage neuroscience company focused on the development and commercialization of therapeutics for the treatment of epilepsy and orphan neurologic disorders characterized by high unmet medical need, announced it will present an analysis of a Phase 3 safety study of VALTOCO® CIV at the 2022 Annual Meeting of the Academy of Managed Care Pharmacy, Oct. 14 to 22, in National Harbor, MD.

Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”) today announced that Mr. James Nathanielsz, Propanc’s Chief Executive Officer, will attend the 43rd Meeting of the European Organization of Research and Treatment of Cancer (EORTC), Pharmacology and Molecular Mechanisms (PAMM) group.

NervGen Pharma Corp., a clinical stage biotech company dedicated to developing innovative solutions for the repair of nervous system damage, today announced it has been awarded up to US$1.5 million in US Department of Defense (DoD) funding from the Military Operational Medicine Research Program to evaluate NervGen’s NVG-291-R as a therapeutic to enable accelerated and enhanced restoration of function following peripheral nerve injury.

VectivBio Holding AG today published the date of the Extraordinary General Meeting, which will be held on Friday, December 9, 2022, at 10:00 a.m. CEST / 4:00 a.m. EDT at the offices of VectivBio Holding AG at Aeschenvorstadt 36, 4051 Basel, Switzerland.

COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the Phase 3 pivotal program design for COMP360 psilocybin therapy in treatment resistant depression (TRD) during a virtual Capital Markets Day.

Biosenta Inc. (the “Company” or “Biosenta”) (CSE: ZRO) has signed a milestone Memorandum of Understanding dated October 5, 2022, with VORAN GROUP VENTURES Ltd. (“Voran”) which will lead the way for the commercialization of Biosenta’s Tri-Filler® antimicrobial products in Canadian markets and worldwide.

PreIPO Corporation™ owner of a suite of proprietary platforms; including: PreIPO-as-a-Service™, Diligence-as-a-Service™, and PreIPO Intelli™, has officially received a full Registered Trademark from the US Patent and Trademark office for “PreIPO®".